HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

‘Inactive’ Label Doesn’t Make Cannabinoids Less Active Or Clear Their Use In OTC Drugs In US

Executive Summary

FDA warns BioLyte Laboratories and Honest Globe about making OTC drugs with cannabinoids. Firms also advised about GMP problems and that labeling cannabinoids as inactive ingredients doesn’t  make their use compliant.

You may also be interested in...



Supplement GMP Warnings Followed After US FDA Restarted Facility Inspections

GMP warnings to firms making supplement firms marketed in US have been rare since FDA temporarily suspended on-site inspections with onset of COVID-19 pandemic. But GMP problems surfaced after agency resumed inspections last July.

Partnership In Israel Cultivates Combining Cannabis And Mushrooms For Supplements

VMS firm Ambrosia-SupHerb partners with cannabis product developer Tikun-Olam to create Israel’s first cannabis and mushroom supplement line.

Wisconsin Doctor’s CBD Nasal Sprays, Topical Offered OTC Diagnosed As Unapproved Drugs

Nasadol CBD Nasal Sprays not only are violative for claims unallowed for CBD, but for containing CBD. FDA also warns online pharmacy about fraudulent OTC COVID-19 cure kit.

Related Content

UsernamePublicRestriction

Register

RS151135

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel